

- transduction of nondividing, fully reimplantable primary hepatocytes. *Mol. Ther.* 6, 199–209.
- Oka, K., Pastore, L., Kim, I.H., Merched, A., Nomura, S., Lee, H.J., Merched-Sauvage, M., Arden-Riley, C., Lee, B., Finegold, M., Beudet, A., and Chan, L. (2001). Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. *Circulation* 103, 1274–1281.
- Ory, D.S., Neugeboren, B.A., and Mulligan, R.C. (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. *Proc. Natl. Acad. Sci. U.S.A.* 93, 11400–11406.
- Overturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.N., Finegold, M., and Grompe, M. (1996). Hepatocytes corrected by gene therapy are selected *in vivo* in a murine model of hereditary tyrosinaemia type I. *Nat. Genet.* 12, 266–273.
- Palmer, D., and Ng, P. (2003). Improved system for helper-dependent adenoviral vector production. *Mol. Ther.* 8, 846–852.
- Park, F., Ohashi, K., Chiu, W., Naldini, L., and Kay, M.A. (2000). Efficient lentiviral transduction of liver requires cell cycling *in vivo*. *Nat. Genet.* 24, 49–52.
- Parks, R.J., Chen, L., Anton, M., Sankar, U., Rudnicki, M.A., and Graham, F.L. (1996). A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. *Proc. Natl. Acad. Sci. U.S.A.* 93, 13565–13570.
- Patijn, G.A., Lieber, A., Schowalter, D.B., Schwall, R., and Kay, M.A. (1998). Hepatocyte growth factor induces hepatocyte proliferation *in vivo* and allows for efficient retroviral-mediated gene transfer in mice. *Hepatology* 28, 707–716.
- Picard-Maureau, M., Kreppel, F., Lindemann, D., Juretzek, T., Herchenroder, O., Rethwilm, A., Kochanek, S., and Heinkelein, M. (2004). Foamy virus—adenovirus hybrid vectors. *Gene Ther.* 11, 722–728.
- Recchia, A., Parks, R.J., Lamartina, S., Toniatti, C., Pieroni, L., Palombo, F., Ciliberto, G., Graham, F.L., Cortese, R., La Monica, N., and Colloca, S. (1999). Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. *Proc. Natl. Acad. Sci. U.S.A.* 96, 2615–2620.
- Robbins, P.B., Skelton, D.C., Yu, X.J., Halene, S., Leonard, E.H., and Kohn, D.B. (1998). Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. *Proc. Natl. Acad. Sci. U.S.A.* 95, 10182–10187.
- Schiedner, G., Morral, N., Parks, R.J., Wu, Y., Koopmans, S.C., Langston, C., Graham, F.L., Beudet, A.L., and Kochanek, S. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved *in vivo* gene expression and decreased toxicity. *Nat. Genet.* 18, 180–183.
- Sena-Esteves, M., Saeki, Y., Fraefel, C., and Breakefield, X.O. (2000). HSV-1 amplicon vectors—simplicity and versatility. *Mol. Ther.* 2, 9–15.
- Serafini, M., Naldini, L., and Introna, M. (2004). Molecular evidence of inefficient transduction of proliferating human B lymphocytes by VSV-pseudotyped HIV-1-derived lentivectors. *Virology* 325, 413–424.
- Soifer, H., Higo, C., Kazazian, H.H., Jr., Moran, J.V., Mitani, K., and Kasahara, N. (2001). Stable integration of transgenes delivered by a retrotransposon-adenovirus hybrid vector. *Hum. Gene Ther.* 12, 1417–1428.
- Soifer, H., Higo, C., Logg, C.R., Jih, L.J., Shichinohe, T., Harboe-Schmidt, E., Mitani, K., and Kasahara, N. (2002). A novel, helper-dependent, adenovirus-retrovirus hybrid vector: Stable transduction by a two-stage mechanism. *Mol. Ther.* 5, 599–608.
- Tan, B.T., Wu, L., and Berk, A.J. (1999). An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency. *J. Virol.* 73, 7582–7589.
- Tateno, C., Yoshizane, Y., Saito, N., Kataoka, M., Utoh, R., Yamasaki, C., Tachibana, A., Soeno, Y., Asahina, K., Hino, H., Asahara, T., Yokoi, T., Furukawa, T., and Yoshizato, K. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. *Am. J. Pathol.* 165, 901–912.
- Umana, P., Gerdes, C.A., Stone, D., Davis, J.R., Ward, D., Castro, M.G., and Lowenstein, P.R. (2001). Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. *Nat. Biotechnol.* 19, 582–585.
- Wivel, N.A., Gao, G.-P., and Wilson, J.M. (1999). Adenovirus vectors. In *The Development of Human Gene Therapy*. T. Friedmann, ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) pp. 87–110.
- Yant, S.R., Ehrhardt, A., Mikkelsen, J.G., Meuse, L., Pham, T., and Kay, M.A. (2002). Transposition from a gutless adenovirus vector stabilizes transgene expression *in vivo*. *Nat. Biotechnol.* 20, 999–1005.


Address correspondence to:

Dr. Shuji Kubo
 Laboratory of Host Defenses
 Institute for Advanced Medical Sciences
 Hyogo College of Medicine
 1-1, Mukogawa-cho, Nishinomiya
 Hyogo 663-8501
 Japan

E-mail: s-kubo@hyo-med.ac.jp

Received for publication February 22, 2009;
 accepted after revision September 2, 2009.

Published online: December 17, 2009.



Suppression of type I collagen production by microRNA-29b in cultured human stellate cells

Tomohiro Ogawa^a, Masashi Iizuka^a, Yumiko Sekiya^{a,b}, Katsutoshi Yoshizato^{a,c}, Kazuo Ikeda^d, Norifumi Kawada^{a,*}

^a Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Japan

^b Toray Industries Inc., Kanagawa, Japan

^c PhoenixBio Co. Ltd., Hiroshima, Japan

^d Department of Functional Anatomy, Graduate School of Medicine, Nagoya City University, Aichi, Japan

ARTICLE INFO

Article history:

Received 6 November 2009

Available online 12 November 2009

Keywords:

Liver fibrosis

SP1

TGF- β

Interferon

TargetScan

ABSTRACT

MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression through imperfect base pairing with the 3' untranslated region (3'UTR) of target mRNA. We studied the regulation of alpha 1 (I) collagen (Col1A1) expression by miRNAs in human stellate cells, which are involved in liver fibrogenesis. Among miR-29b, -143, and -218, whose expressions were altered in response to transforming growth factor- β 1 or interferon- α stimulation, miR-29b was the most effective suppressor of type I collagen at the mRNA and protein level via its direct binding to Col1A1 3'UTR. miR-29b also had an effect on SP1 expression. These results suggested that miR-29b is involved in the regulation of type I collagen expression by interferon- α in hepatic stellate cells. It is anticipated that miR-29b will be used for the regulation of stellate cell activation and lead to antifibrotic therapy.

© 2009 Elsevier Inc. All rights reserved.

Introduction

Hepatic stellate cells, which reside in the Disse's space outside the liver sinusoids, maintain a quiescent phenotype and store vitamin A under physiological conditions [1,2]. When liver injury occurs due to alcohol abuse, hepatitis viral infection, or obesity, stellate cells activate in response to inflammatory stimuli and become myofibroblastic cells that express smooth muscle α -actin as a representative marker [2]. Myofibroblastic cells secrete profibrogenic mediators, such as transforming growth factor- β (TGF- β), connective tissue growth factor, and tissue inhibitor of matrix metalloproteinases, and generate extracellular matrix materials including collagens, fibronectin, and laminin; thus, they play a pivotal role in liver fibrogenesis [3]. In particular, collagen production by activated stellate cells is regulated by TGF- β in an autocrine loop, which is accompanied by the induction of TGF- β receptors [4]. Suppression of hepatic stellate cell activation and collagen expression is thus a critical issue to establish therapeutic strategies for human liver fibrosis [1,5].

Abbreviations: Col1A1, alpha 1 (I) collagen; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; IFN, interferon; miRNAs, microRNAs; TGF- β , transforming growth factor- β ; UTR, untranslated region.

* Corresponding author. Address: Department of Hepatology, Graduate School of Medicine, Osaka City University, 1-4-3, Asahimachi, Abeno, Osaka 545-8585, Japan. Fax: +81 6 6646 9072.

E-mail address: kawadanori@med.osaka-cu.ac.jp (N. Kawada).

MicroRNAs (miRNAs) are endogenous small noncoding RNAs that modulate gene expression through imperfect base pairing with the 3' untranslated region (UTR) of target mRNA, resulting in the inhibition of translation or the promotion of mRNA degradation [6,7]. miRNAs play roles in cell proliferation [8], development [9], and differentiation [10], and their contribution to human diseases such as cancer, cardiomyopathies, and schizophrenia have been reported [11–13]. miR-122 is also involved in the defense system against viral hepatitis C with regard to interferon (IFN)- β therapy [14], and miR-26 expression status is associated with survival and response to adjuvant IFN α therapy in patients with hepatocellular carcinoma [15]. Some miRNAs are involved in liver development and hepatocyte lipid metabolism [16–18].

Recent studies have shown that miRNAs are additionally involved in the alteration of hepatic stellate cell phenotypes; down-regulation of miR-27a and -27b allows culture-activated rat stellate cells to return to a quiescent phenotype with abundant vitamin A storage and decreased cell proliferation [19]; miR-15b and -16, which target the Bcl-2 and caspase signaling pathways, may affect stellate cell activation and liver fibrosis [20]. However, the function of miRNAs in hepatic stellate cell activation and their collagen production is largely unknown.

Here, we show that miR-29b, which is induced in human stellate cells (LX-2) treated with IFN α , is a potential regulator of type I collagen mRNA and protein expression. Although the primary action of IFNs is to eradicate viruses, i.e., hepatitis B and C viruses in

the case of the liver, IFNs also exhibit an antifibrotic action in human chronic hepatitis [21,22] and rodent liver fibrosis models [23]. Our data suggest that miR-29b may be a novel regulator of type I collagen expression in addition to its involvement in the well-known Smad cascade. Moreover, miR-29b upregulation may play a partial role in the antifibrotic action of IFNs.

Materials and methods

Materials. Recombinant human TGF- β 1 was purchased from PeproTech (London, UK). Human natural IFN α was obtained from Otsuka Pharmaceutical Co. (Tokushima, Japan). Precursors of miR-29b, -143, and -218, and the negative control were purchased from Ambion (Austin, TX, USA). Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Rabbit monoclonal antibodies against Smad2 and phospho-Smad2 were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). The mouse monoclonal antibody against SP1 was purchased from Bio Matrix Research Inc. (Chiba, Japan). Rabbit polyclonal antibody against type I collagen was purchased from Rockland Immunochemicals, Inc. (Gilbertsville, PA, USA). Mouse monoclonal antibody against GAPDH was purchased from Chemicon International Inc. (Temecula, CA, USA). Enhanced Chemiluminescence plus detection reagent was purchased from GE Healthcare (Buckinghamshire, UK). Immobilon P membranes were purchased from Millipore Corp. (Bedford, MA, USA). All other reagents were purchased from Sigma Chemical Co. or Wako Pure Chemical Co. (Osaka, Japan).

Preparation of the human hepatic stellate cell line LX-2. The human hepatic stellate cell line (LX-2, donated by Dr. Scott Friedman), which was spontaneously immortalized by growth in low serum, was established as reported previously [24]. Characterizations of the cells are described in detail elsewhere. The cells were maintained on plastic culture plates in DMEM supplemented with 10% FBS. After the culture had continued for the indicated number of days, the medium was replaced with DMEM supplemented with 0.1% FBS plus test agents, and the culture was continued for another 24 h.

Quantitative real-time PCR. Total RNA was extracted from human stellate cells using the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA). cDNAs were synthesized using 0.5 μ g of total RNA, ReverTra Ace (Toyobo, Osaka, Japan), and oligo(dT)_{12–18} primers according to the manufacturer's instructions [25]. Gene expression was measured by real-time PCR using cDNA, real-time PCR Master Mix Reagents (Toyobo), and a set of gene-specific oligonucleotide primers (α 1(I) collagen [Col1A1]: Forward 5'-CCCGGGTTTCAGAGACA ACTTC-3', Reverse 5'-TCCACATGCTTTATCCAGCAATC-3'; TGF- β 1: Forward 5'-AGCGACTCGCCAGAGTGGTTA-3', Reverse 5'-GCAGTG TGTATCCCTGCTGCA-3'; SP1: Forward 5'-TCGGATGAGCTACA GAGGCACAA-3', Reverse 5'-GTCACCTCATGAAGCGCTTAGG-3'; and GAPDH: Forward 5'-GCACCGTCAAGGCTGAGAAC-3', Reverse 5'-TGGTGAAGACGCCAGTGGGA-3') with an Applied Biosystems Prism 7500 (Applied Biosystems, Foster City, CA, USA). To detect miRNA expression, the RT reaction was performed using the TaqMan MicroRNA Assay (Applied Biosystems) according to the manufacturer's instructions. The GAPDH level was measured and used to normalize the relative abundance of mRNAs and miRNAs.

Immunoblot. Proteins (20–50 μ g) were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis and then transferred onto Immobilon P membranes. After blocking, the membranes were treated with primary antibodies, followed by peroxidase-conjugated secondary antibodies. Immunoreactive bands were visualized by the enhanced chemiluminescence system using the Fujifilm Image Reader LAS-3000 (Fuji Medical Systems, Stamford, CT, USA).

Transient transfection of miRNA precursors. Precursors of miR-29b, -143, and -218, and the negative control were transfected into human stellate cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) at a final concentration of 50 nM. Briefly, the cells were plated in DMEM supplemented with 10% FBS at a density of $1–2 \times 10^5$ cells/ml 24 h prior to the transfection. miRNA precursors and Lipofectamine 2000 were mixed at a ratio of 25 (pmol):1 (μ l) in Opti-MEM 1 Reduced Medium (Invitrogen) and incubated for 20–30 min at room temperature. The miRNA precursor–Lipofectamine 2000 complexes were then added to stellate cell culture medium. After 6 h, the culture medium was changed, and TGF- β 1 was added at a concentration of 2 ng/ml.

Luciferase reporter assay. 3'UTRs containing putative miRNA target regions of the Col1A1 and SP1 genes were obtained by PCR using human stellate cell cDNA as a template and primer sets as follows: Col1A1–miR-29: Forward 5'-TTCTCGAGGTCTTGCTTG ATGTGTCACC-3', Reverse 5'-TTTCTAGAGAGAGCAGAGGCCTGAGA AG-3'; Col1A1–miR-143: Forward 5'-CTCGAGACTCCCTCCATCCCAA CCT-3', Reverse 5'-TCTAGAATTGCTGGGACAGACAATAC-3'; Col1A1–miR-218: Forward 5'-CTCGAGGTGGATGGGACTTGTAAT-3', Reverse 5'-TCTAGATTATGTTGGGTCATTCCAC-3'; SP1–miR-29: Forward 5'-TTCTCGAGTGGGTGCTACACAGAATGC-3', Reverse 5'-TTTC TAGAAGACTGTCCTTATTTCTTGTA-3'; and SP1–miR-218: Forward 5'-CTCGAGGATGTTTCCCTAACCTTTCCT-3', Reverse 5'-TCT AGACTAAAAGCTTATATCTCAGCATC-3'. Each of the forward and reverse primers carried the XhoI and XbaI sites at their 5'-ends. The obtained DNA fragments were inserted into the pmirGLO Vector (Promega, San Luis Obispo, CA, USA). The resulting vectors were dubbed pCol1A1–miR-29/mirGLO, pCol1A1–miR-143/mirGLO, pCol1A1–miR-218/mirGLO, pSP1–miR-29/mirGLO, and pSP1–miR-218/mirGLO. Human stellate cells were seeded on 96-well plates (Microtest 96-well Assay Plate; Becton Dickinson, Franklin Lakes, NJ, USA) in DMEM supplemented with 10% FBS at a density of 2×10^4 cells/well. The following day, they were transfected with 200 ng of reporter plasmid along with miRNA precursors using Lipofectamine 2000 as described above and incubated for an additional 24 h. After incubation, the medium was removed from the wells, and 20 μ l of phosphate-buffered saline was added. The Dual-Glo Luciferase Assay System (Promega) was used to analyze luciferase expression according to the manufacturer's protocol. Firefly luciferase activity was normalized to Renilla luciferase activity to adjust for variations in transfection efficiency among experiments.

Statistical analysis. Data presented as bar graphs are the means \pm SD of at least three independent experiments. Statistical analysis was performed using Student's *t*-test, and *P* < 0.05 was considered significant.

Results and discussion

Regulation of Col1A1 expression by TGF- β 1 and IFN α in human stellate cells

Immortalized human stellate cells, LX-2, are classified as an activated phenotype that expresses mRNAs for Col1A1 and other fibrogenetic molecules and are reported to be highly gene-transfectable [24]. At first, we observed that Col1A1 mRNA expression increased dose-dependently by TGF- β 1 (Fig. 1A), whereas this upregulation was significantly inhibited by the presence of 100 IU/ml of human IFN α (Fig. 1B).

Extraction of miR-29b, -143, and -218 as candidates interacting with Col1A1 3'UTR

To determine the role of miRNAs in human stellate cell collagen expression, we searched for predictable miRNAs that could interact




Fig. 1. Regulation of alpha 1(I) collagen (Col1A1) expression in human stellate cells. (A) Dose-dependent effect of TGF-β1 on Col1A1 mRNA expression. Human stellate cells, LX-2, were treated with TGF-β1 (0, 0.08, 0.4, and 2 ng/ml) for 24 h in DMEM containing 0.1% FBS. (B) Effect of IFNα on Col1A1 mRNA expression in human stellate cells stimulated with TGF-β1. The cells were treated with IFNα (100 IU/ml), TGF-β1 (2 ng/ml), or IFNα (100 IU/ml) + TGF-β1 (2 ng/ml) for 24 h in DMEM containing 0.1% FBS. Control: human stellate cells were cultured for 24 h in DMEM containing 0.1% FBS. mRNA expression was analyzed by real-time PCR. The results are expressed as relative expression against control expression without treatment. *P < 0.05; **P < 0.01.

with 3'UTR of human Col1A1 mRNA using TargetScan Human Release 5.1 (<http://www.targetscan.org/>). As a result, miR-29, -98, -129, -133, -143, -196, -218, and let-7 were extracted as candidates. Because further *in silico* analyses among the eight candidates indicated that miR-29b, -143, and -218 were highly homol-

ogous to the Col1A1 3'UTR, we checked the expression levels of these miRNAs in human stellate cells by real-time PCR. As a result, miR-143 and -218 expressions were up and downregulated dose-dependently by TGF-β1, respectively, (Fig. 2A and B). Although miR-29b expression was unaffected by TGF-β1, it increased in




Fig. 2. Expression of miR-29b, -143, and -218 in human stellate cells. (A) Expression of miR-29b, -143, and -218 in human stellate cells, LX-2. The cells were treated with IFNα (100 IU/ml), TGF-β1 (2 ng/ml), or IFNα (100 IU/ml) + TGF-β1 (2 ng/ml) for 24 h in DMEM containing 0.1% FBS. Control: human stellate cells were cultured for 24 h in DMEM containing 0.1% FBS. (B) Dose-dependent effect of IFNα or TGF-β1 on the expression of miR-29b, -143, and -218 in human stellate cells. miRNA expression was analyzed by real-time PCR. The results are expressed as relative expression against control expression without treatment. *P < 0.05; **P < 0.01.




Fig. 3. Interaction of miR-29b, -143, and -218 with the 3'UTRs of alpha 1(I) collagen (Col1A1) and SP1 mRNAs. (A) Schematic indication of the miRNA binding sites in the 3'UTRs of Col1A1 and SP1 mRNAs based on TargetScan Human Release 5.1 (<http://www.targetscan.org/>). Each black, white, and gray box indicates miR-29b, -143, and -218, respectively. Tested sequences indicate the regions that were inserted into the luciferase reporter vector. (B) Predicted consequential pairing of the target region and miRNAs. Arabic numerals above indicate the positions relative to the 3'UTR start sites. (C) Luciferase reporter vector structure. The vector contained two expression units; one for the *Renilla* luciferase gene (*hFluc-neo* fusion) expression. This unit was driven by an SV40 early promoter. The other was for the firefly luciferase gene (*luc2*). This unit was driven by a human phosphoglycerate kinase (PGK) promoter and contained multiple cloning sites (MCS) downstream of the *luc2* sequence. Each Col1A1 and SP1 3'UTR containing a putative miRNA target region (tested sequence) was cloned into the MCS. Arrows indicate the gene directions. Amp^r indicates an ampicillin-resistant plasmid gene. (D) Interaction of miR-29b, -143, and -218 with the 3'UTRs of Col1A1 and SP1 mRNAs in human stellate cells. Relative luciferase activity derived from pCol1A1-miR-29/mirGLO and pSP1-miR-29/mirGLO in the presence of miR-29b precursors (left panel), pCol1A1-miR-143/mirGLO in the presence of miR-143 precursors (center panel), and pCol1A1-miR-218/mirGLO and pSP1-miR-218/mirGLO in the presence of miR-218 precursors (right panel). The pmirGLO vector was used as a negative control reporter vector (control). N: cotransfection of reporter vectors along with negative control precursors, which have a scrambled sequence. P: cotransfection of reporter vectors along with miRNA precursors. Firefly and *Renilla* luciferase activities were determined, and firefly luciferase was normalized to *Renilla* luciferase activity. Results are expressed as relative activities against the activity in the presence of negative control precursors. * $P < 0.05$ and ** $P < 0.01$.

the presence of IFN α (Fig. 2A and B). Thus, we assumed that these miRNAs might affect type I collagen expression via their interaction with Col1A1 3'UTR in human stellate cells.

Interaction of miR-29b, -143, and -218 with 3'UTRs of Col1A1 and SP1 mRNAs

The prediction of miRNA target regions on Col1A1 3'UTR by TargetScan indicated that Col1A1 3'UTR has three target regions for miR-29b, one for miR-143, and one for miR-218 (Fig. 3A and B). Because collagen gene expression is regulated by miR-192 via an interaction with the transcriptional repressor E-box [26], we additionally considered SP1, which is a transcriptional regulator of Col1A1 expression induced by TGF- β 1 [27,28]. The predicted miRNA target regions of SP1 3'UTR contained one target region for miR-29b and one for miR-218 (Fig. 3A and B).

To investigate the direct targeting of Col1A1 by miR-29b, -143, and -218 and that of SP1 by miR-29b and -218, the sequence of each target region was cloned and inserted into the downstream

region of the firefly luciferase reporter gene (Fig. 3C). The resulting vectors were dubbed pCol1A1-miR-29/mirGLO, pCol1A1-miR-143/mirGLO, pCol1A1-miR-218/mirGLO, pSP1-miR-29/mirGLO, and pSP1-miR-218/mirGLO. These vectors were cotransfected into human stellate cells with miRNA precursors. As a result, the miR-29b and -218 precursors inhibited luciferase activity derived from the vectors carrying Col1A1 or SP1 3'UTRs (Fig. 3D). In contrast, the miR-143 precursors had no effect on luciferase activity of the vector carrying Col1A1 3'UTR (Fig. 3D). According to these observations, we assumed that the Col1A1 and SP1 3'UTR sequences could be targeted by miR-29b and -218, whereas miR-143, which was induced by TGF- β 1 (Fig. 2A and B), had a negligible effect on Col1A1 expression in human stellate cells.

Regulation of type I collagen expression by miR-29b and -218

Next, we examined the effect of miR-29b and -218 overexpression on type I collagen mRNA and protein expression in human stellate cells. Transient transfection of miR-29b precursors signifi-




Fig. 4. Effect of miR-29b and -218 on type I collagen expression in human stellate cells. Human stellate cells were cultured in DMEM supplemented with 10% FBS and were transfected with 50 nM miR-29b, -218 precursors, or a negative control, which had a scrambled sequence (control) using Lipofectamine 2000. After 6 h, the medium was changed to DMEM containing 0.1% FBS with or without 2 ng/ml TGF- β 1, and the culture was continued for another 24 h. (A) Effect of miR-29b and -218 precursors on the expression of Col1A1, TGF- β 1, and SP1 mRNAs in human stellate cells with (gray column) or without (white column) TGF- β 1. mRNA expression was analyzed by real-time PCR. The results are expressed as relative expression against control expression. * $P < 0.05$; ** $P < 0.01$. (B) Effect of miR-29b and -218 precursors on the protein expression of phospho-Smad2 (P-Smad2), Smad2, SP1, type I collagen, and GAPDH in human stellate cells in the presence (+) or absence (-) of TGF- β 1.

cantly inhibited type I collagen mRNA and protein expression (Fig. 4A, left panel, and B) in unstimulated human stellate cells. Additionally, transfection of miR-29b precursors completely suppressed the upregulation of type I collagen mRNA and protein under TGF- β 1 stimulation. TGF- β 1 stimulation induces Col1A1 mRNA expression through a pathway that includes SP1 and phosphorylated Smad2/3 [29]. In our results, upregulation of TGF- β 1 mRNA (Fig. 4A, center panel) and phosphorylation of Smad2 (Fig. 4B) under TGF- β 1 stimulation were unaffected by the transfection of miR-29b precursors. These results suggested that miR-29b may affect the downstream of phosphorylated Smad2. Moreover, the transfection of miR-29b precursors decreased SP1 mRNA and protein expression (Fig. 4A, right panel, and B). Thus, the miR-29b-induced repression of type I collagen expression could be caused by its direct interaction with Col1A1 3'UTR and additionally by its interaction with SP1 expression in human stellate cells. These observations agree with a report showing the role of miR-29 in collagen expression and cardiac fibrosis after cardiac infarction [30]. In contrast, transfection of miR-218 precursors triggered a negligible change in Col1A1 and SP1 mRNA expression (Fig. 4A, left and right panels) but slightly reduced their protein level (Fig. 4B). Taken together, these results imply that miR-29b is the most potent miRNA with regard to collagen production in human stellate cells.

Conclusions

We found a potent repression of collagen production by miR-29b in human stellate cells. IFNs attenuate and may regress liver fibrosis caused by hepatitis C viral infection [21–23], although the precise molecular mechanism has yet to be demonstrated.

The present study using human stellate cells demonstrated that IFN α upregulates miR-29b (Fig. 2B and C), which is a negative regulator of type I collagen production via the interaction with Col1A1 and SP1 3'UTRs. This observation implies the contribution of miR-29b to antifibrotic IFN actions. Targeted delivery of miR-29b to activated stellate cells in the liver could become a new therapeutic strategy for human liver fibrosis in the future.

Acknowledgment

This work was supported by a grant from the Ministry of Health, Labour and Welfare of Japan to N. Kawada (2008–2009).

References

- [1] R. Bataller, D.A. Brenner, Hepatic stellate cells as a target for the treatment of liver fibrosis, *Semin. Liver Dis.* 21 (2001) 437–451.
- [2] S.L. Friedman, Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury, *J. Biol. Chem.* 275 (2000) 2247–2250.
- [3] N. Kawada, The hepatic perisinusoidal stellate cell, *Histol. Histopathol.* 12 (1997) 1069–1080.
- [4] S. Dooley, B. Delvoux, B. Lahme, K. Mangasser-Stephan, A.M. Gressner, Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts, *Hepatology* 31 (2000) 1094–1106.
- [5] E. Albanis, S.L. Friedman, Hepatic fibrosis. Pathogenesis and principles of therapy, *Clin. Liver Dis.* 5 (2001) 315–334, v–vi.
- [6] W. Filipowicz, S.N. Bhattacharyya, N. Sonenberg, Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?, *Nat. Rev. Genet.* 9 (2008) 102–114.
- [7] D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function, *Cell* 116 (2004) 281–297.
- [8] J. Brennecke, D.R. Hipfner, A. Stark, R.B. Russell, S.M. Cohen, Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in *Drosophila*, *Cell* 113 (2003) 25–36.

- [9] G.M. Schratt, F. Tuebing, E.A. Nigh, C.G. Kane, M.E. Sabatini, M. Kiebler, M.E. Greenberg, A brain-specific microRNA regulates dendritic spine development, *Nature* 439 (2006) 283–289.
- [10] C.Z. Chen, L. Li, H.F. Lodish, D.P. Bartel, MicroRNAs modulate hematopoietic lineage differentiation, *Science* 303 (2004) 83–86.
- [11] J. Kota, R.R. Chivukula, K.A. O'Donnell, E.A. Wentzel, C.L. Montgomery, H.W. Hwang, T.C. Chang, P. Vivekanandan, M. Torbenson, K.R. Clark, J.R. Mendell, J.T. Mendell, Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model, *Cell* 137 (2009) 1005–1017.
- [12] J.F. Chen, E.P. Murchison, R. Tang, T.E. Callis, M. Tatsuguchi, Z. Deng, M. Rojas, S.M. Hammond, M.D. Schneider, C.H. Selzman, G. Meissner, C. Patterson, G.J. Hannon, D.Z. Wang, Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure, *Proc. Natl. Acad. Sci. USA* 105 (2008) 2111–2116.
- [13] D.O. Perkins, C.D. Jeffries, L.F. Jarskog, J.M. Thomson, K. Woods, M.A. Newman, J.S. Parker, J. Jin, S.M. Hammond, MicroRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder, *Genome Biol.* 8 (2007) R27.
- [14] I.M. Pedersen, G. Cheng, S. Wieland, S. Volinia, C.M. Croce, F.V. Chisari, M. David, Interferon modulation of cellular microRNAs as an antiviral mechanism, *Nature* 449 (2007) 919–922.
- [15] J. Ji, J. Shi, A. Budhu, Z. Yu, M. Forgues, S. Roessler, S. Ams, Y. Chen, P.S. Meltzer, C.M. Croce, L.X. Qin, K. Man, C.M. Lo, J. Lee, I.O. Ng, J. Fan, Z.Y. Tang, H.C. Sun, X.W. Wang, MicroRNA expression, survival, and response to interferon in liver cancer, *N. Engl. J. Med.* 361 (2009) 1437–1447.
- [16] C.E. Rogler, L. Levoci, T. Ader, A. Massimi, T. Tchaikovskaya, R. Norei, L.E. Rogler, MicroRNA-23b cluster microRNAs regulate transforming growth factor-beta/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads, *Hepatology* 50 (2009) 575–584.
- [17] C. Esau, S. Davis, S.F. Murray, X.X. Yu, S.K. Pandey, M. Pear, L. Watts, S.L. Booten, M. Graham, R. McKay, A. Subramaniam, S. Propp, B.A. Lollo, S. Freier, C.F. Bennett, S. Bhanot, B.P. Monia, MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting, *Cell Metab.* 3 (2006) 87–98.
- [18] L. Zheng, G.C. Lv, J. Sheng, Y.D. Yang, Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD, *J. Gastroenterol. Hepatol.* (2009).
- [19] J. Ji, J. Zhang, G. Huang, J. Qian, X. Wang, S. Mei, Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation, *FEBS Lett.* 583 (2009) 759–766.
- [20] C.J. Guo, Q. Pan, D.G. Li, H. Sun, B.W. Liu, MiR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis, *J. Hepatol.* 50 (2009) 766–778.
- [21] Y. Shiratori, F. Imazeki, M. Moriyama, M. Yano, Y. Arakawa, O. Yokosuka, T. Kuroki, S. Nishiguchi, M. Sata, G. Yamada, S. Fujiyama, H. Yoshida, M. Omata, Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy, *Ann. Intern. Med.* 132 (2000) 517–524.
- [22] T. Poynard, J. McHutchison, G.L. Davis, R. Esteban-Mur, Z. Goodman, P. Bedossa, J. Albrecht, Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C, *Hepatology* 32 (2000) 1131–1137.
- [23] Y. Inagaki, T. Nemoto, M. Kushida, Y. Sheng, K. Higashi, K. Ikeda, N. Kawada, F. Shirasaki, K. Takehara, K. Sugiyama, M. Fujii, H. Yamauchi, A. Nakao, B. De Crombrughe, T. Watanabe, I. Okazaki, Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice, *Hepatology* 38 (2003) 890–899.
- [24] L. Xu, A.Y. Hui, E. Albanis, M.J. Arthur, S.M. O'Byrne, W.S. Blaner, P. Mukherjee, S.L. Friedman, F.J. Eng, Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis, *Gut* 54 (2005) 142–151.
- [25] K. Otogawa, T. Ogawa, R. Shiga, K. Nakatani, K. Ikeda, Y. Nakajima, N. Kawada, Attenuation of acute and chronic liver injury in rats by iron-deficient diet, *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 294 (2008) R311–R320.
- [26] M. Kato, J. Zhang, M. Wang, L. Lanting, H. Yuan, J.J. Rossi, R. Natarajan, MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors, *Proc. Natl. Acad. Sci. USA* 104 (2007) 3432–3437.
- [27] L. Li, C.M. Artlett, S.A. Jimenez, D.J. Hall, J. Varga, Positive regulation of human alpha 1 (I) collagen promoter activity by transcription factor Sp1, *Gene* 164 (1995) 229–234.
- [28] I. Garcia-Ruiz, P. de la Torre, T. Diaz, E. Esteban, I. Fernandez, T. Munoz-Yague, J.A. Solis-Herruzo, Sp1 and Sp3 transcription factors mediate malondialdehyde-induced collagen alpha 1 (I) gene expression in cultured hepatic stellate cells, *J. Biol. Chem.* 277 (2002) 30551–30558.
- [29] P. Sysa, J.J. Potter, X. Liu, E. Mezey, Transforming growth factor-beta1 up-regulation of human alpha(1) (I) collagen is mediated by Sp1 and Smad2 transacting factors, *DNA Cell Biol.* 28 (2009) 425–434.
- [30] E. van Rooij, L.B. Sutherland, J.E. Thatcher, J.M. DiMaio, R.H. Naseem, W.S. Marshall, J.A. Hill, E.N. Olson, Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis, *Proc. Natl. Acad. Sci. USA* 105 (2008) 13027–13032.

Review Article

A Human Hepatocyte-Bearing Mouse: An Animal Model to Predict Drug Metabolism and Effectiveness in Humans

Katsutoshi Yoshizato^{1,2} and Chise Tateno¹

¹PhoenixBio, Kagamiyama, 3-4-1 Kagamiya, Higashihiroshima 739-0046, Japan

²Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

Correspondence should be addressed to Katsutoshi Yoshizato, katsutoshi.yoshizato@phoenixbio.co.jp

Received 9 April 2009; Accepted 13 July 2009

Recommended by James P. Hardwick

Preclinical studies to predict the efficacy and safety of drugs have conventionally been conducted almost exclusively in mice and rats as rodents, despite the differences in drug metabolism between humans and rodents. Furthermore, human (*h*) viruses such as hepatitis viruses do not infect the rodent liver. A mouse bearing a liver in which the hepatocytes have been largely repopulated with *h*-hepatocytes would overcome some of these disadvantages. We have established a practical, efficient, and large-scale production system for such mice. Accumulated evidence has demonstrated that these hepatocyte-humanized mice are a useful and reliable animal model, exhibiting *h*-type responses in a series of *in vivo* drug processing (adsorption, distribution, metabolism, excretion) experiments and in the infection and propagation of hepatic viruses. In this review, we present the current status of studies on chimeric mice and describe their usefulness in the study of peroxisome proliferator-activated receptors.

Copyright © 2009 K. Yoshizato and C. Tateno. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

The human (*h*)-body consists of approximately 30 organs, each of which fulfills a specific function, autonomously yet cooperatively with other organs, to maintain life. The liver is essential to *h*-life, as it participates in the control of energy balance and plays central roles in the metabolism and excretion of ingested food and chemicals. Knowledge of the mechanisms underlying the functions of the *h*-liver is important for understanding the biology of the liver as well as for clinically treating liver-damaged patients and for studying drug pharmacology in humans. The ideal approach to elucidating the mechanisms responsible for liver functions would be to perform experiments using the *h*-liver *in situ*, but of course this approach is not realistic. Therefore, scientists have taken two other approaches: *in vitro* examination of samples isolated from the *h*-body (*in vitro*/human), and *in vivo* examinations using animals (*in vivo*/animal). Although these two approaches, separately and together, have revealed much about the mechanisms governing the functions and morphology of the *h*-liver, they are inherently limited by the complexity of the biological phenomena and the species

differences in homologous mechanisms between animals and humans.

The complexity of a biological phenomenon results from the required mutual interactions of multiple different components. The specific cells that represent an organ's functions are collectively termed parenchymal cells. For example, the parenchymal cells of the liver are hepatocyte, because they perform liver-specific functions such as the synthesis and secretion of serum proteins and the synthesis of metabolism-related enzymes, including liver-specific cytochrome P450 (CYP450) proteins. However, hepatocytes by themselves are unable to fulfill liver functions and require the cooperation of nonparenchymal liver cells such as hepatic blood vessels, bile duct biliary cells, Kupffer cells, and stellate cells in the space of Disse, located between the hepatic plate and the sinusoids [1]. The portal vein is the major import route for nutrients to the liver, via the hepatic sinusoids, from the small and most of the large intestine, the spleen, and the pancreas. Nutrients and oxygen in the sinusoids and secretory proteins in the hepatocytes are exchanged through the space of Disse. Stellate cells, the major cell type producing extracellular matrix components in the liver, are located

adjacent to the hepatocytes and the sinusoidal endothelial cells [2]. Hepatocytes, endothelial cells, and stellate cells represent 65, 21, and 6%, respectively, of the *h*-liver and are the main cells responsible for liver functions [1].

Interactive cooperation among different cells types is a principal way in which a multicellular entity is able to function as a living system. It is also a major source of the limitations in *in vitro*/human studies. To date, no studies have successfully reconstituted an *in vitro*/*h*-liver system that perfectly mimics the events that occur in the *h*-liver *in vivo*. This limitation has prompted a search for an *in vivo*/animal experimental system appropriate for providing animal data that can be extrapolated to humans. However, animal models must address the challenge of species differences in the genes and proteins associated with a biological phenomenon.

The liver processes nutrients from the gut and intestines into proteins, lipids, and carbohydrates. It also serves an endocrine function by secreting albumin (Alb), most coagulation factors, several plasma carrier proteins, and lipids into the blood. In addition, the liver synthesizes bile and secretes it into the digestive tract. The elaborate histological structure of the liver optimizes these functions [3]. Hepatocytes are well organized in an aggregated association (the hepatic epithelium) of polarized hepatocytes, creating small apical domains that line the channels between cells (canaliculi). These channels connect to the bile ducts, which drain into the intestine. The basal sides of the hepatocytes are juxtaposed to the fenestrated endothelium of the sinusoids, into which blood flows from the arterial and intestinal portal circulations before emptying into the venous circulation [4].

h-Hepatocytes are indispensable for an *in vitro*/human liver study. Nevertheless, the preparation of *h*-hepatocytes in sufficient numbers for experimental purposes is difficult because the source is very limited and because *h*-hepatocytes do not abundantly proliferate and grow *in vitro*. This led us to create a mouse (*m*) bearing a liver composed almost entirely of *h*-hepatocytes. This approach may simultaneously abolish the limitations of both *in vitro*/human and *in vivo*/animal studies. With this *m*-model, a small number of available *h*-hepatocytes could abundantly proliferate in the *m*-liver for use in *in vitro*/human studies. Furthermore, these mice would provide a superior new type of model animal for *in vivo*/animal studies, because fewer species differences would exist with respect to liver functions.

We have called this type of mouse a "liver-humanized mouse," or simply a chimeric mouse, although the correct name should be "hepatocyte-humanized mouse." The idea of a *h*-liver chimeric mouse was originally described by Brinster's group in 1995 [5] and was actualized by the two groups in 2001 to study *h*-hepatitis B virus (*h*-HBVs) [6] and *h*-HCV infections [7], and later, in 2004, by us to study the *in vivo* growth capacity of *h*-hepatocytes and the gene and protein expression of CYPs [8]. One year later, a detailed morphological study of a chimeric *m*-liver was reported by Meuleman et al. [9]. Kneteman and Mercer briefly reviewed the current chimeric mouse studies [10]. In this article, we review the studies on chimeric mice, including their short historical background, usefulness in testing *h*-type metabolism of clinically usable drugs, and potential

use in examining *h*-type peroxisome proliferator-activated receptors (PPARs), especially PPAR α , which plays key roles in the metabolism of xenobiotics in an animal species-dependent manner. We demonstrate that *h*-hepatocytes propagated in a chimeric *m*-liver and then isolated can serve as normal *h*-hepatocytes for an *in vitro*/human model [11].

2. A Mouse Bearing Transplanted Homogenic and Xenogenic Hepatocytes

To study neonatal bleeding disorders, transgenic mice (Tg_{Alb-uPA}) carrying a tandem array of about four Alb promoter/enhancer-driven urokinase-type plasminogen activator (uPA) genes were created [12]. Their hepatocytes over-produce murine urokinase, and the liver becomes severely hypofibrinogenemic, which accelerates hepatocyte death. Sandgren et al. [13] developed a model of liver regeneration in Tg_{Alb-uPA} mice, in which a chronic stimulus for liver growth was generated due to a functional liver deficit. When a hepatocyte stochastically deleted the deleterious transgene, the hepatocytes of mice hemizygous for the transgene started to replicate and selectively expanded to regain the original size of the liver. Transgene expression in the replicating hepatocytes was abolished because of a DNA rearrangement that affected the transgene tandem array. This permitted the individuals to survive beyond birth, and the plasma uPA concentrations gradually returned to normal by 2 months of age. The transgene-deficient cells formed clonal colonies called hepatic nodules. These nodules expanded and replaced the surrounding transgene-active cells, which could not replicate because of cellular damage. Eventually, the transgene-deficient cells replaced the entire liver. This study demonstrates the usefulness of the Tg_{Alb-uPA} mouse for examining the replicative capacity of not only *m*-hepatocytes, which was successfully done by transplanting hepatocytes isolated from adult mice into the transgenic mice [14], but also hepatocytes of mammals that acquire immunotolerance as follows.

Rhim et al. [5] introduced the Alb-uPA transgene into immunotolerant nu/nu mice by mating Tg_{Alb-uPA} mice with Swiss athymic nude mice, generating immunotolerant Tg_{Alb-uPA} mice (Tg_{Alb-uPA}/NUDE mice). Rat (*r*) liver cells were transplanted into the livers of Tg_{Alb-uPA}^{+/+}/NUDE mice homozygous for the transgene. The host livers that had not been transplanted with *r*-liver cells were completely pale (white). In contrast, those with *r*-liver cells had white regions, representing the area composed only of transgene-expressing host *m*-cells, and red regions, representing the area composed of transgene-deleted host *m*-cells, repopulated *r*-cells, or both. Immunohistochemical analysis with antibodies against *r*-hepatocytes confirmed that the red region was composed primarily of *r*-hepatocytes. The completely regenerated transgenic *m*-livers resemble normal *m*-livers in color, shape, and size. Southern blot analysis demonstrated that up to 56% of the DNA was of rat origin, which agreed well with the parenchymal cell occupancy rate in the liver. These findings strongly support the idea that the host liver was chimeric, with *r*-parenchyma and *m*-nonparenchymal cells,

which included vessels, bile ducts, and associated connective tissues. The ratio of the liver weight to the body weight was 6.8%, which was similar to that of the non-transgenic control mice (5.8%), indicating that the rat-mouse (*r/m*) chimeric livers were able to normally terminate growth. The successful generation of a healthy mouse with a chimeric liver indicates that *r*-parenchymal and *m*-nonparenchymal cells were able to communicate with each other to reconstitute a functional liver, despite the species difference.

Hepatocytes initiate and terminate proliferation under the influence of nonparenchymal cells [1]. Thus, the normal progression and termination of *r/m*-chimeric liver regeneration implies that *r*-hepatocytes produce surface proteins that interact correctly with soluble *m*-factors, *m*-extracellular matrix, and *m*-surface proteins on *m*-nonparenchymal cells. The successful replacement of $Tg_{\text{Alb-uPA}}^{+/+}/\text{NUDE}$ -livers with *r*-hepatocytes raised the exciting possibility that *m*-livers could also be reconstituted with *h*-hepatocytes [5].

3. Repopulation of *h*-Hepatocytes in *m*-Liver

In two previous studies to generate a mouse with a *h*-hepatocyte-mouse (*h/m*) chimeric liver, Rug-2-knockout mice [6] and severe combined immunodeficient (SCID) mice [7] were used as immunodeficient mating partners for uPA transgenic mice. We mated SCID mice (mice_{SCID}) with $Tg_{\text{Alb-uPA}}^{+/+}$ mice to yield liver-injured SCID mice (mice_{Alb-uPA/SCID}) [8]. Normal *h*-hepatocytes, $\sim 10^6$ viable cells per mouse, were transplanted into the livers of these mice at 20–30 days after birth. The *h*-hepatocytes engrafted the liver at rates as high as 96% and progressively repopulated it. The repopulation after *h*-hepatocyte transplantation was easily monitored by the increase in the *h*-Alb concentration in the host blood, and the expansion of *h*-hepatocyte colonies was visualized by immunohistological staining of liver sections with *h*-specific anti-cytokeratin (CK) 8/18 antibodies. The ratio of the number of engrafted *h*-hepatocytes to total hepatocytes (*m*- and *h*-hepatocytes) in the host liver, which is the replacement index (RI), was determined by calculating the ratio of the area occupied by hCK8/18-positive hepatocytes to the entire area examined in immunohistochemical sections of seven lobes. It was demonstrated that sustained engraftment of *h*-hepatocytes occurs in homozygous Alb-uPA transgenic ($Tg_{\text{Alb-uPA}}^{+/+}$) mice, but not in hemizygous transgenic ($Tg_{\text{Alb-uPA}}^{+/-}$) mice. The *h*-hepatocytes started to proliferate around 7 days after transplantation. Their colonies gradually became larger and were almost confluent at around 70 days, when the RI was as high as 96%. Immunohistological staining of liver sections for type IV collagen, laminin, stabilin (a liver endothelial cell marker), BM8 (a Kupffer cell marker), and desmin (a hepatic stellate cell marker) demonstrated the chimeric nature of the liver (Figure 1). The interactions between hepatocytes and stellate cells are critical for physiological and pathological conditions of the liver [15]. Close and seemingly normal associations of *h*-hepatocytes with *m*-stellate cells were immunohistologically visualized by staining with specific antibodies against *h*-CK8/18 (*h*-hepatocytes) and *m*-desmin (*m*-stellate cells)

(Figure 2). These results clearly show that the chimeric *m*-livers with a high RI consisted of parenchymal cells (mostly *h*-cells with a low percentage of *m*-cells), *m*-nonparenchymal cells, and *m*-ECMs, in agreement with a previous study [9]. There was good correlation between the RI and the mRNA expression levels of housekeeping genes such as *h*-Alb and *h*-transferrin, supporting the notion that transplanted *h*-hepatocytes are functional [16]. In our experience, mice with >6 mg/mL *h*-Alb in the blood had an RI $>70\%$. Our histological studies illustrated that the *h*-hepatocytes were well organized and surrounded by *m*-nonparenchymal cells, and they reconstituted the normal tissues specific to a normal functional liver (described in Section 1), despite the large species difference between humans and mice.

We chose robustly growing young mice as hosts. These mice were able to not only survive but also grow, although relatively slowly, and increase their body weight by $>50\%$ of their original weight, during the replacement of host *m*-hepatocytes with *h*-counterparts. These simple animal experiments made us realize that *m*-cells and *h*-hepatocytes were able to mutually communicate to maintain life: *m*-cells supported the proliferation of *h*-hepatocytes, and *h*-hepatocytes supported the growth of the young mouse. The host liver of a mouse_{Alb-uPA/SCID} is congenitally damaged owing to uPA overproduction, low blood levels of Alb, and significantly high levels of alanine aminotransferase (ALT). Repopulation of the *h*-hepatocytes in the liver increased the blood Alb concentration and decreased the ALT level, indicating that *h*-hepatocytes contributed to the improvement of *m*-liver function [8]. Based on these considerations and findings, we expect that a *m*-liver made of *h*-hepatocytes would function as an apparently normal liver, metabolizing and detoxifying endogenous and exogenous biomolecules.

4. Expression Profiles of *h*-Cytchrome P450s in Relation to Phase 1 Metabolic Enzymes

Biochemical treatment of foreign substances (xenobiotics) that have been absorbed into the body is one of the major tasks of the liver. In hepatocytes, xenobiotics are processed to more stable and hydrophilic derivatives by groups of enzymes, collectively called xenobiotic-metabolizing enzymes (XMEs), via two phases: phase 1, which is accomplished by oxidative enzyme, and phase 2, performed by conjugating enzymes [17]. Ingested drugs, toxicants, and chemical carcinogens are metabolized in phase I by CYP and the flavin-containing monooxygenase superfamily. Notably, CYP is the key enzyme in the elimination of clinical drugs.

Humans and rodents respond differently to xenobiotics, and this is explained in part by species differences in CYP subfamilies. These species differences raise serious issues in research for clinically usable medicines, because the results of xenobiotic metabolism studies with mice and rats, which are the most commonly used experimental models for pharmacological and toxicological studies, cannot be extrapolated to humans. Thus, information about the expression of CYP families and subfamilies should be valuable from two viewpoints. First, the expression in *h/m*-chimeric mice of




FIGURE 1: The histological harmonization of *h*-hepatocytes with *m*-nonparenchymal cells. uPA/SCID mice were transplanted with *h*-hepatocytes and allowed to grow until the repopulation of the liver was complete. Then, liver sections were prepared from the *h*-hepatocyte-chimeric mice. Sections were immunostained with *m*-specific antibodies for type IV collagen (a); laminin (b); stabillin (c), a marker of liver endothelial cells (a gift from Dr. A. Miyajima, Tokyo University); and BM8 (d), a marker of Kupffer cells. The immunosignals are brown. The arrows in (c) and (d) point to typical immunopositive cells. Bar, 100 μ m.

a CYP subtype that is found in *h*-hepatocytes, but not in mice, would be a good indication that the *h*-hepatocytes are biochemically functional in the *m*-liver. Second, the *h*-CYP-expressing chimeric mouse is a useful experimental model for studying *h*-type metabolic responses to xenobiotics, including clinically valuable drugs. Of note, CYP3A4 is the most abundantly expressed CYP in *h*-liver and metabolizes >60% of all therapeutic drugs; collectively, CYP2D6 and CYP3A4 metabolize >70% of the drugs on the market [17].

Species differences in the CYP2C subfamily are well known and have been characterized intensively [18, 19]. The *h*-liver contains four CYP2C isoforms, CYP2C8, CYP2C9, CYP2C18, and CYP2C19, all of which are absent from mice and rats. Western blot analyses using *h*-specific antibodies against CYP2C9 revealed positive signals with hepatocytic microsomal fractions from *h/m*-chimeric mice with an RI >34% and from the donor, but not with hepatocytic microsomal fractions from chimeric mice with an RI <28% or from mice that had not been transplanted with *h*-hepatocytes. CYP2C9 catalyzes the 4'-hydroxylation of diclofenac, and the microsomal fractions from the chimeric mice showed diclofenac 4'-hydroxylation activity that depended on the RI of the mouse, strongly suggesting that the *h*-hepatocytes in chimeric livers retain *h*-type pharmacological activity toward drugs. One of the clearest and best-defined examples

of a difference in a CYP between mice and humans is CYP2D6 [20, 21], which is involved in the metabolism of a large number of clinically used drugs [22, 23]. In humans, CYP2D6 is the only active member of the CYP2D subfamily, whereas rats and mice do not express a protein with the enzyme activity of *h*-CYP2D6, although they do have at least five other CYP2D genes [20, 24]. The enzymatic activity of *h*-CYP2D6 in the chimeric mouse was demonstrated by orally administering debrisoquin, a *h*-CYP2D6 substrate, to the mice and subsequently detecting 4'-hydroxydebrisoquin, a major debrisoquin metabolite produced by *h*-CYP2D6, in the blood of the mice. Pretreatment of the mice with quinidine, a typical *h*-CYP2D6 inhibitor, decreased the level of the metabolite. Thus, a CYP enzymatic activity in the chimeric mice was specifically induced by a CYP2D6-metabolized drug and specifically suppressed by a CYP2D6 inhibitor [25].

Among the known CYP families, four families (CYP1–4) play primary roles in XMEs. We compared the mRNA and protein expression profiles of six *h*-CYPs, CYP1A1, 1A2, 2C9, 2C19, 2D6, and 3A4, in the chimeric *m*-liver with those in the donor liver [8]. Total RNA was prepared from the livers of chimeric mice with different RIs and of donors, and the mRNA for the six *h*-CYPs was amplified in a quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR).




FIGURE 2: Close natural apposition of *m*-stellate cells and *h*-hepatocytes in a chimeric liver. A serial section shown in Figure 1 was doubly stained with *h*-CK8/18 (green) for *h*-hepatocytes and *m*-desmin (orange) for *m*-stellate cells. The *h*-hepatocytes are well organized and closely apposed to *m*-stellate cells in Disse's space. Arrows indicate representative *h*-hepatocytes (green) and *m*-stellate cells (orange). Bar, 10 μ m.

All six mRNAs were amplified to detectable levels, which were higher in mice with higher RI values. Thus, the *h*-hepatocytes in the chimeric mice appeared to express the six *h*-CYP genes in a manner similar to their expression in the *h*-body.

We then asked whether these normally expressed *h*-CYPs in the *h/m*-chimeric liver were inducible in a drug-specific manner. The *h*-CYP3A4 and *h*-CYP1A subfamilies specifically respond to rifampicin and 3-methylcholanthrene (3-MC), respectively [26]. Chimeric mice with *h*-hepatocytes were injected intraperitoneally with rifampicin or 3-MC, once per day for 4 days. The mRNA levels of the six *h*-CYPs in the liver tissues were measured 24 h after the last injection. Rifampicin treatment enhanced the expression of *h*-CYP3A4 by 5.8-fold, but did not affect the levels of the other five *h*-CYPs. The administration of 3-MC enhanced CYP1A1 and CYP1A2 mRNA levels by 10.0-fold and 6.4-fold, respectively, but had no effect on the other four CYPs. Neither rifampicin nor 3-MC induced the expression of any of the six *h*-CYPs in mice_{Alb-uPA/SCID} that had not been transplanted with *h*-hepatocytes. Rifabutin, an analogue of rifampicin, also specifically induced *h*-CYP3A, but not the host murine Cyp3a, in the chimeric *m*-liver [27]. The degree of CYP3A4 induction in the chimeric mouse has practical applications in drug testing, because many drugs are CYP3A4 substrates and the induction of CYP3A4 decreases the pharmacological potency of these drugs [17].

Rifampicin is a ligand for the pregnane X receptor (PXR), which forms a heterodimer with retinoid X receptor a (RXRa). Rifampicin/PXR/RXRa subsequently binds to a xenobiotic response element (XRE) composed of the direct repeat of alpha and beta half-sites separated by four nucleotides on the CYP3A4 gene, thereby upregulating its expression in phase I [28]. Rifampicin is a potent activator of human and rabbit PXR, but has little activity

in the rat and mouse [29]. Thus, that the liver data of *h/m*-chimeric mice faithfully reflect those in humans. The binding of 3-MC to the aryl hydrocarbon receptor (AHR) forms a AHR/3-MC complex, which upregulates CYP1A1, CYP1A2, and CYP1B1 expression by binding, together with the AHR nuclear translocator (ARNT), to the XREs of these genes [30]. Our studies suggest that these known ligand-activated receptor signaling pathways activated by rifampicin and 3-MC are functional in the *h/m*-chimeric *m*-liver. Thus, we propose that the hepatocyte-humanized mouse will be a useful animal model in studies of *h*-type signaling pathways that regulate gene expression induced by xenobiotics.

5. Humanization of Phase II Conjugation Pathway of a Drug in *h/m*-Chimeric Mice

It is estimated that phase II conjugation accounts for approximately >30% of drug clearance [31], especially of compounds with polar groups. The major hepatic phase II enzymes in humans are UDP-glucuronosyltransferase (UGT), which is responsible for glucuronidation; sulfotransferase (SULT), for sulfation; *N*-acetyltransferase (NAT), for acetylation; and glutathione *S*-transferase (GST), for glutathione conjugation. We examined the mRNA and protein expression and the enzyme activity of the *h*-forms of these enzymes in chimeric mice with livers having RI values ranging from 0 to 90% [32]. The chimeric livers expressed *h*-UGT, *h*-SULT, *h*-NAT, and *h*-GST mRNA and the UGT2B7, SULT1E1, SULT2A1, and GSTA1 proteins at levels that correlated with their RI values. Activities of related enzymes such as morphine 6-glucuronosyltransferase and estrone 3-sulfotransferase were also detected in an RI-dependent manner. The protein content and enzyme activities of phase II-associated enzymes in chimeric *m*-livers with an RI of approximately 90% were similar to those in the donor liver. In a separate study, we systematically compared the mRNA expression profiles for 26 phase II *h*-enzymes, including GST, SUL, NAT, and UGT members, between livers of chimeric mice with RIs of 71–89% and donor livers [16]. All of the tested enzyme genes were detected. For 65% of the tested genes, the expression levels in the chimeric livers were 30 to 55% of the levels in the donor livers; although lower, these values are comparable to the RI values. These results indicate that the hepatic phase II biotransformation of a drug is appreciably humanized in the *h/m*-chimeric mouse.

There are groups of drugs in clinical use that bind to PXR or constitutive androstane receptors (CARs). The ligand-activated PXR and CARs are involved in the regulation of some phase II XME genes such as SULT1A, UGT1A, and GST [33–35]. Thus, it is likely that these *h*-type ligand-activated transcriptional regulators are functional in *h/m*-chimeric *m*-livers, suggesting that these chimeric mice will contribute to studies on the regulation of gene and protein expression of these transcription factors in relation to xenobiotic metabolism.

6. Drug Transport through the Chimeric *m*-Hepatocyte Membrane

Drug transport in the liver is largely performed by two systems: extrahepatic-to-hepatic transport using transporters such as organic cation transporter 1 (OCT1), organic anion transporting polypeptide (OATP) 1B1, and OATP1B3; and hepatic-to-bile duct transport using adenosine 5'-triphosphate-binding cassette (ABC) proteins, including P-glycoprotein, bile salt export pump (BSEP/ABCB11), breast cancer resistance protein (BCRP/ABCG2), and multidrug resistance-associated protein 2 (MRP2) [36]. The former transporters are located on the sinusoidal membrane and are responsible for the uptake of drugs into hepatocytes; the latter are on the canalicular membrane and are responsible for biliary excretion of the metabolites. The *h*-genes of these transporting systems were preferentially expressed compared with the *m*-counterpart genes in chimeric mice with RIs >60% [36]. Cefmetazole (CMZ), a cephalosporin antibiotic, is excreted without any chemical modification, through urinary and biliary pathways. The urinary pathway is dominant in humans [37], whereas rats [38] and mice [36] use the biliary pathway. Before receiving *h*-hepatocytes, the host mice excreted CMZ primarily through the biliary pathway, but the urinary pathway was dominant in chimeric mice with RIs >60% [36].

The *h*-ABCB4 transporters have been characterized in relation to fibrates-metabolism [39]. In addition, we examined the expression levels of 21 *h*-transporter genes, including members of the ABC, solute carrier (SLC), and OATP families, in the livers of chimeric mice with RIs ranging from 71 to 89%, with respect to the levels in donor livers [16]. For 62% of the tested genes, the expression ratios in the chimeric livers were 0.35 to 0.75. From these limited data, it appears that most of the *h*-type transporter genes were expressed in the chimeric *m*-liver.

7. Infectivity of Chimeric Mice with *h*-Hepatitis Viruses

h-Liver diseases caused by HBV and HCV, especially HCV, are targets for the discovery of efficient antiviral drugs, worldwide [40]. However, the development of effective therapeutics has been hampered by the lack of useful *in vitro* and *in vivo* models of viral replication. For example, cultured *h*-hepatocytes are not appropriate as recipient cells for viral propagation, and rodents are not useful animal models because of the strict species specificity of viral infection [41]. Viral infectivity and propagative potential in the *h/m*-chimeric mouse would be persuasive evidence for concluding that it was actually "humanized." A research group led by Kneteman first challenged chimeric mice with an inoculation of HCV-infected *h*-serum, which produced a virus-infected model mouse [7]. Owing to their substantial advantage in both magnitude and duration of *h*-hepatocyte engraftment, homozygous animals were superior to their hemizygous counterparts in this regard. Initial increases in total viral load were up to 1950-fold, with replication confirmed by the

detection of negative-strand viral RNA in transplanted livers. HCV viral proteins were localized to *h*-hepatocyte nodules, and infection was serially passed through three generations of mice, confirming both synthesis and release of infectious viral particles. Using *h*-hepatocyte-chimeric Rug-2-knockout mice as test animals, Dandri et al. was the first to succeed in producing *in vivo* HBV infection [6].

We studied HBV infectivity in the chimeric mice [42]. After mice were inoculated with *h*-serum containing HBV, a high level of viremia occurred in mice for up to 22 weeks. Passage experiments showed that the serum of these mice contained infectious HBV. As shown previously for HCV, the level of HBV viremia tended to be high in mice with a continuously high RI. Furthermore, lamivudine, an anti-HBV drug, effectively reduced the level of viremia in the infected mice. Thus, the chimeric mouse may be an ideal model in which we can develop and evaluate anti-*h*-hepatitis virus drugs.

8. The *h/m*-Chimeric Mouse as an Animal Model for the Study of *h*-Type Peroxisome Proliferator-Activated Receptors

8.1. Drug Metabolism under The Control of Ligand-Activated Receptors. Biochemical systems in the liver manage not only endogenous (homobiotic), but also xenobiotic molecules. These molecules are first recognized by specific protein receptors on the hepatocyte surface. In general, the binding of a ligand to its receptor generates a signal that ultimately changes gene expression, producing a cellular response. Hepatocytes possess four types of receptors [16], all of which are ligand-activated transcriptional regulators: CAR; PXR [also called steroid X receptor (SXR)]; peroxisome proliferator-activated receptor (PPAR); and aryl hydrocarbon receptor (AHR). The first three belong to the nuclear receptor (NR) superfamily, which consists of seven subfamilies, 1 to 6 and 0 [43]. AHR is a member of the Per-AhR/Arnt-Sim homology sequence (PAS)/basic helix-loop-helix (HLH) superfamily, which also represents the period regulator of circadian rhythm (PER), Ah receptor nuclear translocator (ARNT), and single-minded regulator of midline cell differentiation.

Historically, the roles of PPARs have been studied using liver. They belong to NR subfamily 1, along with thyroid hormone receptor, retinoic acid receptor (RAR), and vitamin D receptor (VDR). As transcription factors, these receptors share a similar process. They are activated by ligand binding; form heterodimers, usually with the retinoid X receptor (RXR); translocate to the nucleus; bind to a *cis*-acting XRE consisting of a direct repeat of two hexanucleotides, separated by one or two nucleotides, in the promoter region of the target gene; and enhance target gene expression [17]. Generally, in the absence of ligand, subfamily 1 NR heterodimers are bound to co-repressor proteins and repress transcription when bound to the *cis*-acting element [44]. Upon ligand binding, the receptor dissociates from the co-repressors and associates with coactivator proteins, which enables the NRs to promote gene expression.

Three PPAR subtypes are currently known [45]: PPAR α (or NR1C1), PPAR β/δ (NR1C2), and PPAR γ (NR1C3). When continuously exposed to certain xenobiotics such as hypolipidemic drugs, plasticizers, and herbicides, which have little apparent structural relationship, rats and mice may show hepatic peroxisome proliferation (increase in volume and number) leading to hepatic tumors; this suggests a correlation between the stimulation of genes for fatty acid β - and ω -oxidation enzymes and the hepatic neoplastic process [46, 47]. Reddy and Rao [48] proposed that specific soluble binding sites for these drugs, collectively termed peroxisome proliferators (PPs), were present in liver and kidney cell extracts [49, 50]. The PPAR gene was first cloned as a member of the steroid hormone receptor superfamily from a *m*-hepatic cDNA library [51]. This gene corresponds to PPAR α , according to the current nomenclature. Two years later, three closely related members of the PPAR family (xPPAR α , β , and γ) were isolated from a *Xenopus* ovary cDNA library and were shown to activate the promoter of the acyl coenzyme A oxidase (ACO) gene, which encodes the key peroxisomal fatty acid β -oxidation enzyme [52]. xPPAR α is homologous to Issemann's PPAR α [51], and xPPAR γ is currently placed in the PPAR γ subfamily, together with other homologous members found in mammals. Mammalian PPAR δ was in a new PPAR group because of a difference in amino acid sequence compared with xPPAR β ; however, it is presently considered to be a PPAR β and is designated as PPAR β/δ [45]. Of the three PPARs, PPAR α is the most critical in the present review, because it is expressed at high levels in the liver, activates fatty acid catabolism, stimulates gluconeogenesis and ketone body synthesis, and participates in the control of lipoprotein assembly [45].

8.2. Species Differences in PPAR α -Associated Signaling. The PPAR α isotype has prime importance for studies with animal models to predict the effects of hepatic PPs in humans, because PPAR α agonists induce seemingly quite different actions in rodents and humans [53]. Originally, as the name indicates, PPARs were studied because of their ability to bind PPs and consequently induce PP-metabolizing enzymes. In rats and mice, but not in humans, PPs such as hypolipidemic drugs, industrial plasticizers, and herbicides are non-genotoxic carcinogens that cause liver tumors [54]. In humans, these drugs function to maintain lipid homeostasis and do not induce peroxisome proliferation. Thus, the toxicity and carcinogenicity of PPs are highly species specific [55]. The species differences may be attributable to lower PPAR mRNA expression levels in *h*-hepatocytes compared with rodent cells [56, 57]. Alternatively, or additionally, species differences may be the result of different sensitivities of the genes associated with the peroxisome proliferation response to low levels of PPs, owing to structural differences in PPAR α [54]. There are both similarities and differences in responses to xenobiotics among not only different species (interspecies) but also individuals of the same species (intraspecies). Interspecific PPAR α diversity between rodents and humans is well known and has been studied with respect to drug metabolism. NR subfamily 1

members have at least two functions in mammals. One is to regulate peroxisome proliferation through binding to PPAR response elements (PPREs) in the promoters of genes such as ACO [58, 59], bifunctional dehydrogenase/hydratase (BFE) [60], and microsomal CYP4A1 [61]. The other is to modulate the serum cholesterol level by targeting genes such as the lipoprotein lipase gene [62] and the apolipoprotein regulating genes AI, AII, and CII [63]. The former mechanism appears to function in rodents, but not in humans, and is responsible for the induction of peroxisome proliferation and hepatocarcinogenesis, whereas the latter mechanism controls basic lipid metabolism in both rodents and humans [56]. This species difference in xenobiotic receptor/ligand signaling may be attributable to differences in the expression level of a receptor, or to differences in receptor/ligand binding affinity, and causes difficulty in determining responses in humans based on rodent data [56].

8.3. PPAR α Gene-Humanized Mice. One approach to overcoming species differences is to generate "humanized" transgenic mice (gene-humanized mice), in which a *h*-gene of interest is introduced into the *m*-genome [17]. A PPAR α gene-humanized *m*-line that expresses the *h*-PPAR α gene [64] under the control of the tetracycline responsive regulatory system in the liver of murine PPAR α gene-null mice [65] has been created. These mice functionally responded to the expected ligands as wild-type mice, but did not exhibit the hepatocellular proliferation, including increases in peroxisomes, seen in wild-type mice. Thus, this approach may help overcome species differences and provide animal models suitable for studying *h*-responses regulated by genes of interest.

8.4. PPAR Signaling in Chimeric Mice. Considering the prominent roles and the species divergence of PPARs in the response to xenobiotics, it is important to study *h*-PPAR-related responses of the *h/m*-chimeric mouse. We examined the effects of fibrates (antihyperlipidemic drugs and PPAR agonists) [63, 66] in the chimeric mice. Given the central role of the liver in PPAR-regulated lipid metabolism and the use of fibrate compounds in a variety of clinical drugs, the responses of *h/m*-chimeric mice to fibrates and PPARs may have important practical implications.

Hepatocytes secrete biliary phospholipids, composed largely of phosphatidylcholine (PC), through multidrug-resistance 2 P-glycoprotein (MDR3, or ABCB4) embedded in the canalicular membrane. MDR3 was shown to translocate PC in a study using *mdr2* gene (a murine homolog of *h*-MDR3) knockout mice. These mice completely lack phospholipids in their bile [67], but the bile PC is fully recovered with the overexpression of *h*-MDR3 [68]. The expression level of the *h*-MDR3 gene affects the development of hepatobiliary diseases [69].

Fibrates upregulate *mdr2* gene expression [70], which is associated with an increase in biliary phospholipid secretion [71]. Bezafibrate (BF), a second-generation fibrate analog, was clinically shown to reduce elevated serum biliary enzyme levels in patients with chronic cholestatic liver disease

[72]. It was shown to bind to PPAR β/δ and α , with a higher affinity for the former, and was thus said to be a bona fide PPAR ligand [73]. Other researchers created a coactivator-dependent receptor-ligand in vitro interaction assay and demonstrated that BF was a ligand for PPAR α , β/δ , and γ [74]. The same researchers also showed drug-induced activation of PPAR α /RXR α , PPAR β/δ /RXR α , and PPAR γ /RXR α [74].

BF induces an increase in ABCB4 (MDR3), and its redistribution in the cell membrane. This induction was associated with an enhanced capacity of *h*-hepatocytes to direct PC into bile canaliculi [75]. Furthermore, ABCB4 redistribution was attenuated when PPAR α expression was suppressed by small interfering RNA or morpholino antisense oligonucleotides in cultured HepG2 cells (hepatoblastoma cells) [75], strongly suggesting the necessity for PPAR α in the BF-induced activation of PC secretion in *h*-hepatocytes.

We tested the ability of the *h/m*-chimeric *m*-liver to exhibit *h*-type PPAR-dependent responses by administering BF to the chimeric mice. Mice with RIs of 60–80% were fed a standard laboratory chow containing 0.3% (wt/wt) BF for 7 days, and their livers were analyzed for MDR3 mRNA and protein expression [39]. The mRNA level in the BF-treated mice was approximately 2-fold the level in non-treated control mice. The protein level was approximately 3.5-fold that in the controls. The fibrate induced a robust redistribution (exocytosis and insertion) of MDR3 proteins into the bile canaliculi.

Although studies on the expression and function of PPARs in the *h/m*-chimeric *m*-liver are limited, we conclude, based on the studies described above, that the chimeric *m*-liver exhibits the phenotypes of PPAR-regulated physiological and pathological processes, including responses to xenobiotics, that are normally present in the *h*-liver in vivo.

9. Summary and Prospective

After administration, a xenobiotic is generally and largely absorbed by the liver, intracellularly distributed, metabolized, and secreted through the bile or urinary ducts. These steps, collectively termed absorption, distribution, metabolism, and excretion (ADME), are interdependent, and drug pharmacokinetics are determined by the parameters resulting from these interactive processes. There are marked species differences in the many genes and proteins associated with ADME of a xenobiotic. The differences between humans and rodents dictate that pharmacokinetic data determined in rodents must be very cautiously, deliberately, and correctly extrapolated to humans in order to ensure that the drug will be safe and effective in patients. Until recently, *h*-hepatocyte-chimeric mice have been studied primarily in relation to CYP-associated metabolism, representing the M of ADME, and HCV/HBV infection. These studies have shown that the chimeric mice are significantly and appreciably humanized, providing a reliable and promising animal model for predicting drug metabolism and efficacy in humans. Although data have also been accumulated for the A, D, and E

steps of ADME, more work is required before reaching an appropriate conclusion concerning the humanization of a chimeric mouse with respect to these processes. Nevertheless, currently available data appear to demonstrate that these processes are also well humanized.

Based on our studies and experiences to date, the *h*-hepatocyte-chimeric mice exhibit *h*-type liver responses at the gene and protein levels. These mice can mimic the steady-state expression in the *h*-liver in the absence of exogenous stimuli and exhibit the expected *h*-type responses upon stimulation. However, we must consider the limitations of chimeric mice. Current chimeric mice carry hepatocytes only of human origin, but all other cells are of *m*-origin. To perform liver functions, parenchymal cells require non-parenchymal cells, which are of mouse, and not of human, origin in the chimeric mice. Some interactions between *h*-hepatocytes and *m*-nonparenchymal cells may proceed as normal homogeneous interactions, and some may not.

In addition, endocrinological regulation is crucial for hepatocytes to achieve normal metabolic homeostasis and to return to normal conditions after endogenous or exogenous factors have caused metabolic parameters to extend beyond the normal range. Chimeric livers are under the influence of the *m*-endocrinological system, and some *m*-hormones such as growth hormone (GH) are not able to act on *h*-cells, because a hormone-receptor complex does not form between *m*-GH and *h*-hepatocyte receptors [76]. In support of this notion, *h*-hepatocytes administered with *h*-GH showed enhanced expression of liver growth-associated *h*-genes, including IGF-1, STAT-3, Cdc 25A, and cyclinD1, and repopulated the host liver at a rate approximately 6-fold that in the control. Despite these possible limitations, we consider the chimeric mouse to be the best animal model to date for *h*-liver function studies, because the chimeric mice with high RI values not only expressed *h*-liver proteins but also mimicked *h*-liver functions. Five years ago, we started mass production of homogenous populations of the hepatocyte-humanized mice with high RIs to facilitate research activities in the academic and industrial communities, including examinations of *h*-type metabolism of new drugs for *h*-use, the study of *h*-HCV infection mechanism and propagation, and the development of new anti-HCV-drugs. However, we are still in the initial stages of characterizing various aspects of the chimeric mice. Further study will systematically reveal the advantages and limits of this newly developed hepatocyte-humanized mouse.

Acknowledgments

The authors are grateful to Dr. Hardwich for the kind invitation to review the current status of the studies on chimeric mice, with an emphasis on PPAR signaling, as this will be an important issue in the utilization of chimeric mice for drug development. We thank Drs. T. Yokoi, T. Horie, and T. Inoue for kindly providing information related to PPAR-associated drug metabolism; Ms. T. Shimizu for assistance in preparing the manuscript; and Dr. A. Miyajima for kindly permitting us to present Figure 1 in our review.

We are much obliged to a recent review [1] on historical and histological aspects of chimeric mice, some parts of which are cited herein, and to an excellent review [17] that presented information on recent progress in xenobiotic metabolism studies, especially those using gene-engineered humanized mice to evaluate *h*-type xenobiotic metabolism. Our study of chimeric mice with livers composed of *h*-hepatocytes was supported by three programs, the Yoshizato project, Cooperative Link of Unique Science and Technology for Economy Revitalization (CLUSTER), Japanese Ministry of Education, Culture, Sports, Science, and Technology, the Hiroshima Prefecture to K. Yoshizato, Hiroshima University 21st Century COE Program for Advanced Radiation Casualty Medicine to K. Kamiya, and Advanced Medical Technology, Health, and Labor Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan to T. Yokoi.

References

- [1] K. Yoshizato, C. Tateno, and R. Utoh, "A human hepatocytes-bearing mouse: a novel animal model to study the mechanism of liver size control in mammals," *International Journal of Design & Nature*, vol. 4, no. 2, pp. 1–20, 2009.
- [2] K. Nakatani, H. Okuyama, Y. Shimahara, et al., "Cytoglobin/STAP, its unique localization in splanchnic fibroblast-like cells and function in organ fibrogenesis," *Laboratory Investigation*, vol. 84, no. 1, pp. 91–101, 2004.
- [3] F. Lemaigre and K. S. Zaret, "Liver development update: new embryo models, cell lineage control, and morphogenesis," *Current Opinion in Genetics & Development*, vol. 14, no. 5, pp. 582–590, 2004.
- [4] G. K. Michalopoulos, "Liver regeneration," *Journal of Cellular Physiology*, vol. 213, no. 2, pp. 286–300, 2007.
- [5] J. A. Rhim, E. P. Sandgren, R. D. Palmiter, and R. L. Brinster, "Complete reconstitution of mouse liver with xenogeneic hepatocytes," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 11, pp. 4942–4946, 1995.
- [6] M. Dandri, M. R. Burda, E. Török, et al., "Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus," *Hepatology*, vol. 33, no. 4, pp. 981–988, 2001.
- [7] D. F. Mercer, D. E. Schiller, J. F. Elliott, et al., "Hepatitis C virus replication in mice with chimeric human livers," *Nature Medicine*, vol. 7, no. 8, pp. 927–933, 2001.
- [8] C. Tateno, Y. Yoshizane, N. Saito, et al., "Near completely humanized liver in mice shows human-type metabolic responses to drugs," *American Journal of Pathology*, vol. 165, no. 3, pp. 901–912, 2004.
- [9] P. Meuleman, L. Libbrecht, R. De Vos, et al., "Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera," *Hepatology*, vol. 41, no. 4, pp. 847–856, 2005.
- [10] N. M. Kneteman and D. F. Mercer, "Mice with chimeric human livers: who says supermodels have to be tall?" *Hepatology*, vol. 41, no. 4, pp. 703–706, 2005.
- [11] M. Nishimura, T. Yokoi, C. Tateno, et al., "Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver," *Drug Metabolism and Pharmacokinetics*, vol. 20, no. 2, pp. 121–126, 2005.
- [12] J. L. Heckel, E. P. Sandgren, J. L. Degen, R. D. Palmiter, and R. L. Brinster, "Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator," *Cell*, vol. 62, no. 3, pp. 447–456, 1990.
- [13] E. P. Sandgren, R. D. Palmiter, J. L. Heckel, C. C. Daugherty, R. L. Brinster, and J. L. Degen, "Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene," *Cell*, vol. 66, no. 2, pp. 245–256, 1991.
- [14] J. A. Rhim, E. P. Sandgren, J. L. Degen, R. D. Palmiter, and R. L. Brinster, "Replacement of diseased mouse liver by hepatic cell transplantation," *Science*, vol. 263, no. 5150, pp. 1149–1152, 1994.
- [15] N. Kawada, D. B. Kristensen, K. Asahina, et al., "Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells," *The Journal of Biological Chemistry*, vol. 276, no. 27, pp. 25318–25323, 2001.
- [16] M. Nishimura, H. Yoshitsugu, T. Yokoi, et al., "Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver," *Xenobiotica*, vol. 35, no. 9, pp. 877–890, 2005.
- [17] F. J. Gonzalez and A.-M. Yu, "Cytochrome P450 and xenobiotic receptor humanized mice," *Annual Review of Pharmacology and Toxicology*, vol. 46, pp. 41–64, 2006.
- [18] N. J. Hewitt, E. L. Lecluyse, and S. S. Ferguson, "Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations," *Xenobiotica*, vol. 37, no. 10-11, pp. 1196–1224, 2007.
- [19] M. J. Graham and B. G. Lake, "Induction of drug metabolism: species differences and toxicological relevance," *Toxicology*, vol. 254, no. 3, pp. 184–191, 2008.
- [20] J. J. P. Bogaards, M. Bertrand, P. Jackson, et al., "Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man," *Xenobiotica*, vol. 30, no. 12, pp. 1131–1152, 2000.
- [21] J. Caldwell, "The current status of attempts to predict species differences in drug metabolism," *Drug Metabolism Reviews*, vol. 12, no. 2, pp. 221–237, 1981.
- [22] U. M. Zanger, S. Raimundo, and M. Eichelbaum, "Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry," *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 369, no. 1, pp. 23–37, 2004.
- [23] A.-M. Yu, J. R. Idle, and F. J. Gonzalez, "Polymorphic cytochrome P450, 2D6: humanized mouse model and endogenous substrates," *Drug Metabolism Reviews*, vol. 36, no. 2, pp. 243–277, 2004.
- [24] Y. Masubuchi, T. Iwasa, S. Hosokawa, et al., "Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes," *Journal of Pharmacology and Experimental Therapeutics*, vol. 282, no. 3, pp. 1435–1441, 1997.
- [25] M. Katoh, T. Sawada, Y. Soeno, et al., "In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver," *Journal of Pharmaceutical Sciences*, vol. 96, no. 2, pp. 428–437, 2007.
- [26] W. P. Bowen, J. E. Carey, A. Miah, et al., "Measurement of cytochrome P450 gene induction in human hepatocytes, using quantitative real-time reverse transcriptase-polymerase chain reaction," *Drug Metabolism and Disposition*, vol. 28, no. 7, pp. 781–788, 2000.
- [27] M. Katoh, T. Matsui, M. Nakajima, et al., "In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver," *Drug Metabolism and Disposition*, vol. 33, no. 6, pp. 754–763, 2005.
- [28] T. Toriyabe, K. Nagata, T. Takada, et al., "Unveiling a new essential cis element for the transactivation of the CYP3A4

- gene by xenobiotics," *Molecular Pharmacology*, vol. 75, no. 3, pp. 677–684, 2009.
- [29] S. A. Jones, L. B. Moore, J. L. Shenk, et al., "The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution," *Molecular Endocrinology*, vol. 14, no. 1, pp. 27–39, 2000.
- [30] I. J. Cho and S. G. Kim, "Oltipraz inhibits 3-methylcholanthrene induction of CYP1A1 by CCAAT/enhancer-binding protein activation," *The Journal of Biological Chemistry*, vol. 278, no. 45, pp. 44103–44112, 2003.
- [31] T. D. Bjornsson, J. T. Callaghan, H. J. Einolf, et al., "The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective," *Drug Metabolism and Disposition*, vol. 31, no. 7, pp. 815–832, 2003.
- [32] M. Katoh, T. Matsui, H. Okumura, et al., "Expression of human phase II enzymes in chimeric mice with humanized liver," *Drug Metabolism and Disposition*, vol. 33, no. 9, pp. 1333–1340, 2005.
- [33] W. Xie, M.-F. Yeuh, A. Radominska-Pandya, et al., "Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 7, pp. 4150–4155, 2003.
- [34] S. Kodama, C. Koike, M. Negishi, and Y. Yamamoto, "Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes," *Molecular and Cellular Biology*, vol. 24, no. 18, pp. 7931–7940, 2004.
- [35] J. Zhang, W. Huang, S. S. Chua, P. Wei, and D. D. Moore, "Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR," *Science*, vol. 298, no. 5592, pp. 422–424, 2002.
- [36] H. Okumura, M. Katoh, T. Sawada, et al., "Humanization of excretory pathway in chimeric mice with humanized liver," *Toxicological Sciences*, vol. 97, no. 2, pp. 533–538, 2007.
- [37] H. Ko, E. Novak, G. R. Peters, et al., "Pharmacokinetics of single-dose cefmetazole following intramuscular administration of cefmetazole sodium to healthy male volunteers," *Antimicrobial Agents and Chemotherapy*, vol. 33, no. 4, pp. 508–512, 1989.
- [38] T. Murakawa, H. Sakamoto, S. Fukada, et al., "Pharmacokinetics of ceftizoxime in animals after parenteral dosing," *Antimicrobial Agents and Chemotherapy*, vol. 17, no. 2, pp. 157–164, 1980.
- [39] J. Shoda, K. Okada, Y. Inada, et al., "Bezafibrate induces multidrug-resistance P-glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice," *Hepatology Research*, vol. 37, no. 7, pp. 548–556, 2007.
- [40] S. A. Sarbah and Z. M. Younossi, "Hepatitis C: an update on the silent epidemic," *Journal of Clinical Gastroenterology*, vol. 30, no. 2, pp. 125–143, 2000.
- [41] P. Meuleman and G. Leroux-Roels, "The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV," *Antiviral Research*, vol. 80, no. 3, pp. 231–238, 2008.
- [42] M. Tsuge, N. Hiraga, H. Takaishi, et al., "Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus," *Hepatology*, vol. 42, no. 5, pp. 1046–1054, 2005.
- [43] Nuclear Receptors Nomenclature Committee, "A unified nomenclature system for the nuclear receptor superfamily," *Cell*, vol. 97, no. 2, pp. 161–163, 1999.
- [44] S. Yu and J. K. Reddy, "Transcription coactivators for peroxisome proliferator-activated receptors," *Biochimica et Biophysica Acta*, vol. 1771, no. 8, pp. 936–951, 2007.
- [45] L. Michalik, J. Auwerx, J. P. Berger, et al., "International union of pharmacology. LXI. Peroxisome proliferator-activated receptors," *Pharmacological Reviews*, vol. 58, no. 4, pp. 726–741, 2006.
- [46] E. A. Lock, A. M. Mitchell, and C. R. Elcombe, "Biochemical mechanisms of induction of hepatic peroxisome proliferation," *Annual Review of Pharmacology and Toxicology*, vol. 29, pp. 145–163, 1989.
- [47] M. R. Nemali, M. K. Reddy, N. Usuda, et al., "Differential induction and regulation of peroxisomal enzyme: predictive value of peroxisome proliferation in identifying certain non-mutagenic carcinogens," *Toxicology and Applied Pharmacology*, vol. 97, no. 1, pp. 72–87, 1989.
- [48] J. K. Reddy and M. S. Rao, "Peroxisome proliferators and cancer: mechanisms and implications," *Trends in Pharmacological Sciences*, vol. 7, pp. 438–443, 1986.
- [49] N. D. Lalwani, W. E. Fahl, and J. K. Reddy, "Detection of a nafenopin binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidemic compounds," *Biochemical and Biophysical Research Communications*, vol. 116, no. 2, pp. 388–393, 1983.
- [50] S. Goldfischer and J. K. Reddy, "Peroxisomes (microbodies) in cell pathology," *International Review of Experimental Pathology*, vol. 26, pp. 45–84, 1984.
- [51] I. Issemann and S. Green, "Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators," *Nature*, vol. 347, no. 6294, pp. 645–650, 1990.
- [52] C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahli, "Control of the peroxisomal β -oxidation pathway by a novel family of nuclear hormone receptors," *Cell*, vol. 68, no. 5, pp. 879–887, 1992.
- [53] K. Tachibana, D. Yamasaki, K. Ishimoto, and T. Doi, "The role of PPARs in cancer," *PPAR Research*, vol. 2008, Article ID 102737, 15 pages, 2008.
- [54] K. Morimura, C. Cheung, J. M. Ward, J. K. Reddy, and F. J. Gonzalez, "Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor α to Wy-14,643-induced liver tumorigenesis," *Carcinogenesis*, vol. 27, no. 5, pp. 1074–1080, 2006.
- [55] P. Bentley, I. Calder, C. Elcombe, P. Grasso, D. Stringer, and H.-J. Wiegand, "Hepatic peroxisome proliferation in rodents and its significance for humans," *Food and Chemical Toxicology*, vol. 31, no. 11, pp. 857–907, 1993.
- [56] P. R. Holden and J. D. Tugwood, "Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences," *Journal of Molecular Endocrinology*, vol. 22, no. 1, pp. 1–8, 1999.
- [57] C. N. A. Palmer, M.-H. Hsu, K. J. Griffin, J. L. Raucy, and E. F. Johnson, "Peroxisome proliferator activated receptor- α expression in human liver," *Molecular Pharmacology*, vol. 53, no. 1, pp. 14–22, 1998.
- [58] J. D. Tugwood, I. Issemann, R. G. Anderson, K. R. Bundell, W. L. McPheat, and S. Green, "The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene," *The EMBO Journal*, vol. 11, no. 2, pp. 433–439, 1992.
- [59] B. Zhang, S. L. Marcus, F. G. Saijadi, et al., "Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase," *Proceedings of the National*

- Academy of Sciences of the United States of America*, vol. 89, no. 16, pp. 7541–7545, 1992.
- [60] O. Bardot, T. C. Aldridge, N. Latruffe, and S. Green, "PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene," *Biochemical and Biophysical Research Communications*, vol. 192, no. 1, pp. 37–45, 1993.
- [61] T. C. Aldridge, J. D. Tugwood, and S. Green, "Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription," *Biochemical Journal*, vol. 306, part 2, pp. 473–479, 1995.
- [62] K. Schoonjans, J. Peinado-Onsurbe, A.-M. Lefebvre, et al., "PPAR α and PPAR γ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene," *The EMBO Journal*, vol. 15, no. 19, pp. 5336–5348, 1996.
- [63] J. M. Peters, N. Hennuyer, B. Staels, et al., "Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α -deficient mice," *The Journal of Biological Chemistry*, vol. 272, no. 43, pp. 27307–27312, 1997.
- [64] C. Cheung, T. E. Akiyama, J. M. Ward, et al., "Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor α ," *Cancer Research*, vol. 64, no. 11, pp. 3849–3854, 2004.
- [65] S. S. Lee, T. Pineau, J. Drago, et al., "Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators," *Molecular and Cellular Biology*, vol. 15, no. 6, pp. 3012–3022, 1995.
- [66] C.-H. Lee, P. Olson, and R. M. Evans, "Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors," *Endocrinology*, vol. 144, no. 6, pp. 2201–2207, 2003.
- [67] J. J. M. Smit, A. H. Schinkel, R. P. J. Oude Elferink, et al., "Homozygous disruption of the murine *mdr2* P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease," *Cell*, vol. 75, no. 3, pp. 451–462, 1993.
- [68] A. J. Smith, J. M. L. de Vree, R. Ottenhoff, R. P. J. Oude Elferink, A. H. Schinkel, and P. Borst, "Hepatocyte-specific expression of the human *MDR3* P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in *Mdr2* (-/-) mice," *Hepatology*, vol. 28, no. 2, pp. 530–536, 1998.
- [69] O. Rosmorduc, B. Hermelin, P.-Y. Boelle, R. Parc, J. Taboury, and R. Poupon, "ABC $B4$ gene mutation-associated cholelithiasis in adults," *Gastroenterology*, vol. 125, no. 2, pp. 452–459, 2003.
- [70] T. Kok, V. W. Bloks, H. Wolters, et al., "Peroxisome proliferator-activated receptor α (PPAR α)-mediated regulation of multidrug resistance 2 (*Mdr2*) expression and function in mice," *Biochemical Journal*, vol. 369, part 3, pp. 539–547, 2003.
- [71] J. Chianale, V. Vollrath, A. M. Wielandt, et al., "Fibrates induce *mdr2* gene expression and biliary phospholipid secretion in the mouse," *Biochemical Journal*, vol. 314, part 3, pp. 781–786, 1996.
- [72] T. Kurihara, A. Niimi, A. Maeda, M. Shigemoto, and K. Yamashita, "Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid," *American Journal of Gastroenterology*, vol. 95, no. 10, pp. 2990–2992, 2000.
- [73] G. Krey, O. Braissant, F. L'Horsset, et al., "Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay," *Molecular Endocrinology*, vol. 11, no. 6, pp. 779–791, 1997.
- [74] I. Inoue, F. Itoh, S. Aoyagi, et al., "Fibrate and statin synergistically increase the transcriptional activities of PPAR α /RXR α and decrease the transactivation of NF κ B," *Biochemical and Biophysical Research Communications*, vol. 290, no. 1, pp. 131–139, 2002.
- [75] J. Shoda, Y. Inada, A. Tsuji, et al., "Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPAR α -mediated redistribution of ABC $B4$," *Journal of Lipid Research*, vol. 45, no. 10, pp. 1813–1825, 2004.
- [76] N. Masumoto, C. Tateno, A. Tachibana, et al., "GH enhances proliferation of human hepatocytes grafted into immunodeficient mice with damaged liver," *Journal of Endocrinology*, vol. 194, no. 3, pp. 529–537, 2007.

Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice[☆]

Nobuhiko Hiraga^{1,2}, Michio Imamura^{1,2}, Tsuyoshi Hatakeyama¹, Shosuke Kitamura¹, Fukiko Mitsui^{1,b}, Shinji Tanaka¹, Masataka Tsuge^{1,2}, Shoichi Takahashi^{1,2}, Hiromi Abe^{2,3}, Toshiro Maekawa^{2,3}, Hidenori Ochi^{2,3}, Chise Tateno^{2,4}, Katsutoshi Yoshizato^{2,4,5}, Takaji Wakita⁶, Kazuaki Chayama^{1,2,3,*}

¹Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan

²Liver Research Project Center, Hiroshima University, Hiroshima, Japan

³Laboratory for Liver Diseases, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN), Yokohama, Japan

⁴PhoenixBio Co., Ltd., Higashihiroshima, Japan

⁵Osaka City University Graduate School of Medicine, Osaka, Japan

⁶Department of Virology II, National Institute of Infectious Diseases, Shinjuku-ku, Japan

Background/Aims: Both hepatitis B virus (HBV) and hepatitis C virus (HCV) replicate in the liver and show resistance against innate immunity and interferon (IFN) treatment. Whether there is interference between these two viruses is still controversial. We investigated the interference between these two viruses and the mode of resistance against IFN.

Methods: We performed infection experiments with either or both of the two hepatitis viruses in human hepatocyte chimeric mice. Huh7 cell lines with stable production of HBV were also established and transfected with HCV JFH1 clone. Mice and cell lines were treated with IFN. The viral levels in mice sera and culture supernatants and messenger RNA levels of IFN-stimulated genes were measured.

Results: No apparent interference between the two viruses was seen *in vivo*. Only a small (0.3 log) reduction in serum HBV and a rapid reduction in HCV were observed after IFN treatment, regardless of infection with the other virus. In *in vitro* studies, no interference between the two viruses was observed. The effect of IFN on each virus was not affected by the presence of the other virus. IFN-induced reductions of viruses in culture supernatants were similar to those in *in vivo* study.

Conclusions: No interference between the two hepatitis viruses exists in the liver in the absence of hepatitis. The mechanisms of IFN resistance of the two viruses target different areas of the IFN system.

© 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Keywords: Superinfection; JFH-1; IFN-stimulated genes

Received 4 February 2009; received in revised form 14 July 2009; accepted 15 July 2009; available online 23 September 2009

Associate Editor: F. Zoulim

[☆] C.T. and K.Y. are employees of PhoenixBio Co. Ltd., Higashihiroshima, Japan. The other authors who have taken part in this study declared that they do not have anything to disclose regarding funding from industry or conflict of interest with respect to this manuscript.

* Corresponding author. Tel.: +81 82 2575190; fax: +81 82 2556220.

E-mail address: chayama@hiroshima-u.ac.jp (K. Chayama).

Abbreviations: GAPDH, glyceraldehydes-3-phosphate dehydrogenase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; IFN, interferon; OAS, 2',5'-oligoadenylate synthetase; PCR, polymerase chain reaction; SCID, severe combined immunodeficiency; uPA, urokinase-type plasminogen activator.

0168-8278/\$36.00 © 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.jhep.2009.09.002

1. Introduction

Both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are serious health problems worldwide. More than 350 million people are infected with HBV, and more than 170 million people are infected with HCV [1,2]. Both types of hepatitis viruses result in the development of chronic liver infection and lead to death due to liver failure and hepatocellular carcinoma [3]. To date, interferon (IFN) remains one of the most important drugs available for the treatment of both types of hepatitis viral infections. Although it is assumed that IFN suppresses viral replication through the effect of IFN-induced gene products such as mixovirus resistance protein A (MxA), RNA-dependent protein kinase (PKR), and 2',5'-oligoadenylate synthetase (OAS) [4], the precise mechanism of action of these proteins on both hepatitis viruses are unknown.

Coinfection with both viruses leads to a rapid and severe progression of chronic liver disease [5], with a higher risk of hepatocellular carcinoma [6]. Currently, there is a debate about whether or not there is interference between the two hepatitis viruses, with some favoring such interference [7] and others arguing against such a concept [8]. A number of mechanisms can cause interference between viruses. A major mechanism of interference is induction of IFN by one virus to prevent replication of the second virus; however, viruses develop their own strategies to resist the effect of IFN. In clinical practice, practitioners often perceive that reduction of HBV in serum by IFN therapy is poorer compared with HCV. HCV levels in sera of IFN-treated patients decrease relatively rapidly, and a proportion of patients eventually show complete eradication of the virus. Furthermore, the recent use of pegylated IFN (PEG-IFN) in combination with ribavirin has improved the eradication rate [9]. Eradication of HBV by IFN, however, is usually difficult, even when using IFN combined with ribavirin [10].

The mechanisms developed by viruses to resist host innate immunity, including IFN signaling, are well established in some viruses. Such mechanisms involve interruption of IFN signaling by interacting molecules that transduce the signal from the IFN receptor through the Janus kinase (Jak) signal transducer and activator of transcription (STAT) pathway [4]. Viral proteins of paramyxoviruses, for example, inhibit IFN signaling [11]. Several studies have also examined the mechanisms by which HCV resists the host immune system. These include degradation of Cardif adaptor protein by NS3A/4 protease [12]. Generally, expression of HCV protein is associated with inhibition of STAT1 function independent of STAT tyrosine phosphorylation [13]. Additionally, expression of the HCV core protein in cultured cells is associated with increased expression levels of the suppressor of cytokine signaling 3 (SOCS-3) [14]. The NS5A and E2 proteins are both inhibitors of PKR

[15]. These strong actions of HCV against innate immunity are consistent with the high chronicity rate of the virus. IFN, however, effectively reduces HCV replicon in Huh7 cells [16], suggesting that the virus has little potential to disturb the actions of IFN.

In contrast to HCV, the mechanisms of IFN resistance by HBV are poorly understood. To date, only a few studies have reported the molecular mechanisms of HBV resistance against the actions of IFN. The HBV-related resistance to IFN, for example, involves upregulation of protein phosphatase 2A (PP2A) as the primary event, which subsequently leads to inhibition of protein arginine methyltransferase 1 (PRMT1) and reduced STAT1 methylation [17]. In addition to these molecular mechanisms, microarray analyses of serial liver biopsies of experimentally infected chimpanzees showed striking differences in the early immune responses to HBV and HCV. HCV, for example, induced early changes in the expression of many intrahepatic genes, including genes involved in type 1 IFN response [18], whereas HBV did not induce any detectable changes in the expression of intrahepatic genes in the first weeks of infection [19].

HBV–HCV double infection is a good model to use for assessment of the mechanism of IFN resistance by these two viruses because one can test the effect of IFN on one virus in the presence of the other virus. Recently, Bellecave et al. [20] established a novel *in vitro* model system in Huh7 cells that allowed the analysis of both viruses in a replicating context and reported the absence of direct viral interference. To this end, we used human hepatocyte chimeric mice and cell culture systems in the present study. The results showed that the presence of HBV does not affect the actions of IFN on HCV and vice versa. These results suggest the lack of interference between the two viruses in liver cells and indicate that the reported interference between the two viruses might be via inflammation including death of infected cells by cytotoxic T cells, cytokines including IFN- α and IFN- β , and interleukins produced by hepatocytes and infiltrating T cells.

2. Materials and methods

2.1. Transfection of Huh7 cells with HBV DNA and HCV RNA

Huh7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum at 37 °C and under 5% CO₂. Cloning of HBV DNA and the plasmid construction were performed as described previously [21]. For production of stably transfected cell lines, Huh7 cells were seeded onto 90-mm-diameter culture dishes. Twenty micrograms of the plasmid pTRE-HB-wt [21] was transfected by the calcium phosphate precipitation method. Twenty-four hours after transfection, the cells were split and cultured in Hygromycin B-DMEM selection medium (300 μ g/ml; Invitrogen Japan K.K., Osaka, Japan), while 50 colonies were isolated and cultured for identification of virus-producing cell lines. Clones positive